Iron overload in myelodysplastic syndromes (MDS)

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Iron overload (IOL) develops in myelodysplastic syndromes (MDS) due to ineffective erythropoiesis and suppressed hepcidin, leading to increased iron absorption.
• Chronic transfusion therapy is the primary driver of IOL in MDS patients, negatively impacting survival, particularly in lower-risk cases.
• IOL contributes to cardiac dysfunction, endothelial dysfunction, and atherosclerotic progression, exacerbating bone marrow failure by affecting stromal and hematopoietic cells.

Purpose of the Study:

• To review the mechanisms and consequences of iron overload in myelodysplastic syndromes.
• To evaluate the efficacy of iron chelation therapy in managing IOL and improving outcomes in MDS patients.

Main Methods:

• Literature review of studies on iron metabolism in MDS.
• Analysis of patient series and clinical trials investigating iron chelators.
• Examination of registry data on iron chelation and survival in MDS.

Main Results:

• Iron overload is initiated by ineffective erythropoiesis and exacerbated by transfusions, impacting survival and organ function.
• Iron chelators like deferoxamine and deferasirox have shown potential to improve hematopoiesis in some transfusion-dependent MDS patients.
• Registry data suggest survival benefits from iron chelation, though prospective randomized trial data are pending.

Conclusions:

• Iron overload is a significant complication in MDS, contributing to disease progression and reduced survival.
• Iron chelation therapy is a potential therapeutic strategy for MDS patients with IOL, warranting further investigation.
• Prospective randomized trials are crucial to definitively establish the survival benefit of iron chelation in MDS.